Chronic meningococcaemia is a relatively benign manifestation of meningococcal disease. Whether bacterial virulence factors are responsible for this benign course has not been studied. We compared the in vitro endotoxin-liberating ability and cytokine-inducing potential of 31 Neisseria meninigitidis isolates obtained from children with acute septic shock with that of nine isolates obtained from patients with chronic meningococcaemia and 12 isolates obtained from carriers with respiratory symptoms. The median endotoxin level released in vitro after 3 h of incubation was significantly higher for isolates causing septic shock compared with isolates from the other two groups (P=0.01 and 0.02, Mann-Whitney test). This was not explained by differences in bacterial growth rate in vitro. The median IL-6 levels in whole blood ex vivo after 4 h of incubation were also significantly lower for isolates causing chronic meningococcaemia (P=0.04, Mann-Whitney test). The endotoxin and cytokine levels measured on admission in the 31 children with acute meningococcal septic shock showed a 1000-fold variation. No relationship was established between the amount of endotoxin released by the causative microorganisms in vitro and the endotoxin or cytokine levels in the corresponding 31 children. These results suggest a diminished bacterial virulence for isolates causing chronic meningococcaemia. However, other factors than the endotoxin-releasing potential of the microorganism involved are responsible for the wide variation in endotoxin and therefore cytokine levels in patients with acute meningococcal septic shock.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1905093PMC
http://dx.doi.org/10.1046/j.1365-2249.1998.00715.xDOI Listing

Publication Analysis

Top Keywords

chronic meningococcaemia
20
septic shock
16
isolates causing
12
endotoxin cytokine
12
cytokine levels
12
bacterial virulence
8
children acute
8
mann-whitney test
8
causing chronic
8
acute meningococcal
8

Similar Publications

Article Synopsis
  • Hemoglobinopathies like sickle cell disease and thalassemia lead to health complications, increasing infection risks, making vaccinations essential for patient care and quality of life.
  • A nationwide survey in Greece assessed vaccination coverage and attitudes toward vaccination among patients with hemoglobinopathies using a 37-item anonymous questionnaire.
  • Results showed that while childhood vaccination rates were generally in line with national standards, adult vaccination coverage was low for several key vaccines, particularly among individuals over 50 years, who also had more misconceptions about vaccinations.
View Article and Find Full Text PDF

Rationale & Objective: Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) caused by complement dysregulation. Ravulizumab is a C5i approved for the treatment of aHUS. This analysis assessed long-term outcomes of ravulizumab in adults and pediatric patients with aHUS.

View Article and Find Full Text PDF
Article Synopsis
  • - PNH is a serious condition that leads to blood issues, and pegcetacoplan is a new therapy that targets a specific part of the immune system to help treat it; clinical trials show it works well and is safe for patients.
  • - In a follow-up study (307 OLE), 137 patients who received pegcetacoplan showed significant improvements in hemoglobin levels and reduced fatigue, with most not needing blood transfusions over the study period.
  • - Results indicated 40.2% of patients achieved hemoglobin levels above 12 g/dL, and while some experienced hemolysis, there were no major complications like blood clots or infections reported.
View Article and Find Full Text PDF

Human papillomavirus (HPV) vaccination prevents the development of HPV-associated malignancies. Adolescent and young adult survivors of childhood cancers and patients with sickle cell disease (SCD) are vulnerable patient populations who would significantly benefit from HPV vaccination. In this multimethod study, a retrospective chart review found a notable difference between the rate of HPV vaccinations and other age-appropriate vaccinations in 177 childhood cancer survivors and in 70 patients with SCD.

View Article and Find Full Text PDF

Background: Individuals who receive allogeneic hematopoietic cell transplant (allo-HCT) are immunocompromised and at high risk of pneumococcal infections, especially in the months following transplant. This study evaluated the safety and immunogenicity of V114 (VAXNEUVANCE; Merck, Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!